Skip to search formSkip to main contentSkip to account menu

SP 100030

Known as: SP-100030, SP100030 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Organic Chemicals

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Both AP-1 and NF-kappaB seem to be involved in tumour growth in an experimental rat hepatoma.
Daily treatment of rats bearing Yoshida AH-130 ascites hepatoma with the nuclear factor kappa-B (NF-kappaB) and activator protein… 
Highly Cited
2007
Highly Cited
2007
The AP-1/NF-kappaB double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia.
Daily treatment of rats bearing the cachectic Yoshida AH-130 ascites hepatoma with the double inhibitor of NF-kappaB and AP-1… 
2007
2007
Inhibition of Nuclear Factor-κB in T Cells Suppresses Lung Fibrosis
Rationale: Cytokines secreted by T cells play a pivotal role in the pathogenesis of lung injury and fibrosis, and the… 
2007
2007
Inhibition of nuclear factor-kappaB in T cells suppresses lung fibrosis.
RATIONALE Cytokines secreted by T cells play a pivotal role in the pathogenesis of lung injury and fibrosis, and the… 
2001
2001
A novel transcription factor inhibitor, SP100030, inhibits cytokine gene expression, but not airway eosinophilia or hyperresponsiveness in sensitized and allergen‐exposed rat
We examined the effect of SP100030, a novel inhibitor of activator protein‐1 (AP‐1) and nuclear factor (NF)‐κB transcription… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)